Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel induction followed by S-1 chemoradiotherapy in locally advanced pancreatic cancer
jRCTs041180073Phase 2Completed
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel and tegafur in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC). Primary endpoint: Overall survival. Started Oct 2017; status: completed.
02
Drugs
gemcitabinepaclitaxeltegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041180073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180073.